Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bd89f7dbf77bb51928b847f7e7a4dabd4> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bd89f7dbf77bb51928b847f7e7a4dabd4 NCIT_P378 "NCI" @default.
- Bd89f7dbf77bb51928b847f7e7a4dabd4 type Axiom @default.
- Bd89f7dbf77bb51928b847f7e7a4dabd4 annotatedProperty IAO_0000115 @default.
- Bd89f7dbf77bb51928b847f7e7a4dabd4 annotatedSource NCIT_C180889 @default.
- Bd89f7dbf77bb51928b847f7e7a4dabd4 annotatedTarget "An agonistic antibody targeting the human cell surface glycoprotein CD226 (DNAX accessory molecule-1; DNAM-1), with potential immunostimulatory and antineoplastic activities. Upon administration, anti-CD226 agonist antibody LY3435151 targets and binds to CD226 on a variety of immune cell types, including T-cells, natural killer (NK) cells, B-cells and monocytes. This induces CD226-dependent signaling pathways, which may trigger the activation of antigen-presenting cells (APCs) and activate T-cells and NK cells. This may result in an enhanced cytotoxic T-lymphocyte (CTL)-mediated and NK cell-mediated immune response against tumor cells. CD226, a cell surface glycoprotein that functions as an adhesion molecule, is expressed on various immune cells and plays an important role in the co-activation of T-cells and NK cells upon interaction with its ligands CD155 and CD112." @default.